Vertex Pharmaceuticals EV/EBIT VRTX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026: 26.6×
9-year median: 26.0×
Against its 9-year history: 51st; percentile: 0 is its lowest day, 100 its highest
9-year range: 10.7× to 134×
Peer median: 17.8×

Vertex Pharmaceuticals' EV/EBIT is 26.6× as of Oct 23, 2026.

That is above its 9-year median of 26.0×, close to the middle of its last 9 years.

Over that time it ranged from 10.7× in Nov 2021 to 134× in Jul 2017.

The median for 8 biotech stocks of a similar size is 17.8×.

EV/EBIT over time

median 26×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	26.6×	22.2×	27.8×
2025	25.8×	20.7×	30.0×
2024	24.3×	22.0×	31.0×
2023	22.3×	12.4×	22.6×
2022	12.4×	10.7×	14.7×
2021	13.1×	10.7×	21.1×
2020	21.0×	18.9×	72.7×
2019	66.6×	43.5×	74.8×
2018	61.3×	59.3×	111×
2017	80.8×	75.7×	134×
2016	n/m a value too high to mean anything
2015	n/m a value too high to mean anything
2014	n/m a value too high to mean anything
2013	30.7×	30.1×	31.5×
2012	26.9×	14.5×	39.4×

Against its peers

Companies in Biotechnology nearest Vertex Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
VRTXVertex Pharmaceuticals	26.6×
REGNRegeneron Pharmaceuticals	20.0×
ONCBeOne Medicines	42.2×
ALNYAlnylam Pharmaceuticals	27.9×
UTHRUnited Therapeutics	16.1×
INCYIncyte	10.1×
EXELExelixis	15.4×
NBIXNeurocrine Biosciences	18.2×
HALOHalozyme Therapeutics	17.4×
Peer median	17.8×

Where Vertex Pharmaceuticals ranks

#11of 17Biotech stocks with the lowest EV/EBIT

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Vertex Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.